STE

$220.13

Post-MarketAs of Mar 17, 8:00 PM UTC

STERIS plc provides infection prevention products and services worldwide.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$220.13
Potential Downside
34.6%
Whystock Fair Value$143.87
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assuran...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
30.74
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Strong income play. Yield provides a meaningful total return floor.
112.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
10.47%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.53

Recent News

Simply Wall St.
Mar 16, 2026

A Look At STERIS (STE) Valuation After Recent Share Price Weakness

What stands out about STERIS right now STERIS (STE) has drawn attention after a stretch of weaker share performance, with the stock down about 14% over the past month and 15% over the past 3 months, despite ongoing revenue and net income growth. See our latest analysis for STERIS. At a share price of $214.57, STERIS has a 1 day share price return of 1.05%, a 30 day share price return of 13.60%, and a 1 year total shareholder return of 4.87%. Recent weakness therefore contrasts with a still...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barchart
Mar 16, 2026

Is STERIS Stock Underperforming the Nasdaq?

STERIS has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 11, 2026

3 Healthcare Stocks We Think Twice About

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 4.1% over the past six months, almost identical to the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 6, 2026

Steris (STE) Down 2.2% Since Last Earnings Report: Can It Rebound?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.